Fertl E, Auff E, Doppelbauer A, Waldhauser F
Department of Neurology, University of Vienna, Austria.
J Neural Transm Park Dis Dement Sect. 1991;3(1):41-7. doi: 10.1007/BF02251135.
Although several studies on the efficacy and the toxicity of exogenous melatonin in Parkinson patients have been carried out, there are no data available on melatonin secretion in these patients. We therefore performed a controlled trial in 9 Parkinson patients (aged 62.1 +/- 8.7 years, x +/- SD) and in 14 control persons (58.0 +/- 10.4 years). Parkinson patients were treated with l-dopa (300-1000 mg per day) in combination with a peripheral decarboxylase inhibitor (benserazide, carbidopa). 14 venous blood samples were taken from each person during a period of 24 hours in order to investigate the circadian secretion pattern of melatonin. Serum melatonin levels were estimated by radioimmuno assay. We found that the circadian secretion patterns of l-dopa-treated Parkinson patients and age-matched controls were very similar except for a phase advance of the nocturnal melatonin elevation in the parkinsonian group.
尽管已经对外源性褪黑素在帕金森病患者中的疗效和毒性进行了多项研究，但尚无这些患者褪黑素分泌情况的数据。因此，我们对9例帕金森病患者（年龄62.1±8.7岁，x±标准差）和14名对照者（58.0±10.4岁）进行了一项对照试验。帕金森病患者接受左旋多巴（每日300 - 1000毫克）联合外周脱羧酶抑制剂（苄丝肼、卡比多巴）治疗。在24小时内从每个人采集14份静脉血样本，以研究褪黑素的昼夜分泌模式。通过放射免疫分析法测定血清褪黑素水平。我们发现，除了帕金森病组夜间褪黑素升高出现相位提前外，接受左旋多巴治疗的帕金森病患者和年龄匹配的对照者的昼夜分泌模式非常相似。
